Abstract:Introduction Neoadjuvant chemotherapy (NAC) is the standard-of-care (SOC) for patients with locally advanced triple-negative breast cancer (TNBC) [1]. Unfortunately, only about half of TNBC patients achieve a pathological complete response (pCR) at the completion of NAC [2]. With the recent FDA approval of immunotherapy, the response rate improved by about 8% [3]. To try to further improve NAC response rates, we build upon methods that predict treatment response to optimize interventions and outcomes. Our previous studies have demonstrated that excellent predictive accuracy of TNBC response to NAC was achieved through calibrating mechanism-based models to both pre- and on- treatment imaging data [4]. However, by requiring on-treatment imaging data, therapy optimization can only occur after a patient begins NAC. Here, our goal is to relax the requirement of on-treatment imaging data such that we can predict, and potentially optimize, a patient's response to NAC before initiating it. We will accomplish this through combining data-driven approaches with mechanism-based modeling to obtain spatiotemporal predictions of tumor response prior to NAC. More specifically, we integrate a reaction-diffusion equation based mathematical model with a U-Net based convolutional neural network (CNN). Methods The reaction-diffusion equation models the development of tumor cellularity over time as the sum of tumor cell diffusion, controlled by a fixed diffusivity, and tumor cell proliferation, controlled by a calibrated net proliferation rate. The net proliferation rate implicitly accounts for both proliferative and drug induced death effects. We calibrated the net proliferation rates in this model on a patient-specific basis for 128 patients from the ARTEMIS trial (NCT02276443) using three imaging timepoints – pre- (V1), post two cycles (V2), and post four cycles (V3) of A/C. We then employed a CNN to characterize the relationship between the calibrated net proliferation rates and the pre-treatment imaging data. The CNN takes pretreatment imaging inputs of the apparent diffusion coefficient map, percent enhancement maps from the dynamic contrast enhanced MRI timecourse, and precontrast T1 map. The CNN outputs an estimate of the calibrated net proliferation rate which can be used to run the mathematical model forward in time to predict cellularity maps at V2/3. In training the CNN, our loss considers both the concordance correlation coefficient (CCC) and the normalized root mean square error (NRMSE). We calculated loss on the net proliferation rate predictions as NRMSE with a CCC penalty to aid in characterizing the non-Gaussian distribution of the net proliferation rate. We calculated loss on the cellularity predictions as the CCC between predicted and measured voxel-wise cellularity. The CNN was trained using the Adam optimizer and a fivefold cross validation with a withheld test set of 26 patients. Results Using the CNN predictions to forward run the mechanism-based model in time to V3 we calculated change in total tumor cellularity and volume from V1 to V3. In the test cohort, we obtained CCC values between the predicted and measured changes of 0.95 and 0.91 for cellularity and volume, respectively. Discussion and summary Through integrating mechanistic modeling and deep learning, we can accurately predict the spatiotemporal development of TNBC response to NAC using only pretreatment imaging data. We will build upon these results by expanding our model to include separate proliferation and drug induced death terms to allow for therapy intervention and optimization. Additionally, we will incorporate other pretreatment data types including genetic data. [1] Liedtke et al., J of Clin Oncol, 2008. [2] Spring et al., Clin Cancer Res, 2020. [3] Schmid et al., NEJM, 2020. [4] Wu et al., Cancer Res, 2022. Citation Format: Casey Stowers, Chengyue Wu, Sidharth Kumar, Zhan Xu, Clinton Yam, Jong Bum Son, Jingfei Ma, Jonathan Tamir, Gaiane Rauch, Thomas Yankeelov. Integrating mechanism-based and data-driven modeling to predict the response of triple negative breast cancer to therapy [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO5-07-03.

Optimizing Neoadjuvant Treatment Response Prediction for Triple-Negative Breast Cancer Using Clinical Trial Data and Deep Auxiliary Learning

An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Multimodal machine learning model prediction of complete pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.

Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI

Personalized chemotherapy selection for patients with triple-negative breast cancer using deep learning

Abstract 845: Developing MRI-based digital-twins via mathematical modeling and deep learning to predict the response of triple-negative breast cancer to neoadjuvant therapy

Abstract PD11-07: Integrated model for early prediction of neoadjuvant systemic therapy response in triple negative breast cancer

Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer

Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer

Prediction of early clinical response to neoadjuvant chemotherapy in Triple-negative breast cancer: Incorporating Radiomics through breast MRI

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer

Deep learning-based prediction of response to HER2-targeted neoadjuvant chemotherapy from pre-treatment dynamic breast MRI: A multi-institutional validation study

Abstract PO5-07-03: Integrating mechanism-based and data-driven modeling to predict the response of triple negative breast cancer to therapy

Comparative Evaluation of Machine Learning Models for Subtyping Triple-Negative Breast Cancer: A Deep Learning-Based Multi-Omics Data Integration Approach

Deep Learning Framework for Comprehensive Molecular and Prognostic Stratifications of Triple-Negative Breast Cancer

Abstract B038: A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer

Abstract 2736: Forecasting treatment response to neoadjuvant therapy in triple-negative breast cancer via an image-guided digital twin

Cross-modal deep learning model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer

Predicting Relapse in Patients With Triple Negative Breast Cancer (TNBC) Using a Deep-Learning Approach

Deep Learning and Digital Pathology Power Precision Treatment of Triple-Negative Breast Cancer

Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer